Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $154

Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $154

Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $143 to $154.

byBenzinga Newsdesk

January 12, 2023

1 minute read

Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $143 to $154.

Nasdaq Surges 100 Points; CoreCivic Shares Plummet

By Avi Kapoor

June 11, 2:31 PM

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 100 points on…

AISP

Raymond James Maintains Outperform on Azul, Lowers Price Target to $12

By Benzinga Newsdesk

July 7, 8:28 AM

Raymond James analyst Savanthi Syth maintains Azul (NYSE:AZUL) with a Outperform and lowers the price target from $22 to $12.

AZUL

Truist Securities Maintains Buy on Dollar Tree, Lowers Price Target to $168

By Benzinga Newsdesk

Today, 9:24 AM

Truist Securities analyst Scot Ciccarelli maintains Dollar Tree (NASDAQ:DLTR) with a Buy and lowers the price target from $178 to $168.

DLTR

Transphorm Enters Into Agreements To Raise $9.3M From The Exercise Of Existing Warrants And A Private Placement Of Common Stock

By Happy Mohamed

April 3, 9:19 AM

Transphorm, Inc. (NASDAQ:TGAN) ("Transphorm" or the "Company"), a pioneer in and global supplier of high-reliability, high-performance gallium nitride (GaN) power conversion products, announced today

TGAN

Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $154

Related Posts

Nasdaq Surges 100 Points; CoreCivic Shares Plummet

Raymond James Maintains Outperform on Azul, Lowers Price Target to $12

Truist Securities Maintains Buy on Dollar Tree, Lowers Price Target to $168

Transphorm Enters Into Agreements To Raise $9.3M From The Exercise Of Existing Warrants And A Private Placement Of Common Stock